miRNA Biomarker Panel for Predicting Post-TBI Epilepsy Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for predicting which patients with traumatic brain injury (TBI) will develop epilepsy, and there is a lack of reliable predictors for post-brain insult epileptogenesis, leading to unnecessary treatment with anti-epileptic drugs.
Innovation Solution
The use of specific microRNA (miRNA) biomarkers, such as Let-7d-5p, miR-340-3p, miR-484, miR-151, miR-350, miR-770-5p, miR-139-3p, miR-2985, miR-101a-5p, miR-206-3p, miR-760-3p, miR-383-5p, and miR-294-5p, to diagnose susceptibility to epilepsy by detecting their abnormal expression in blood samples, allowing targeted treatment with anti-epileptogenic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If miRNA biomarker detection methods are implemented, then predictive accuracy for epilepsy susceptibility is improved, but device complexity and assay complexity increase
Solution Approach 1:
The patent segments the complex diagnostic problem into detection of specific miRNA biomarkers (let-7d-5p, miR-340-3p, miR-484, miR-151, miR-350) individually, allowing each biomarker to be assessed separately through targeted assays, thereby improving predictive accuracy while managing complexity through focused measurement
Solution Approach 2:
The patent changes the measurement parameter from general neurological assessment to specific miRNA expression levels, using quantitative detection of biomarker concentrations to predict epilepsy susceptibility with high accuracy despite the complexity of the molecular assays required
2Measurement precision
If miRNA biomarker detection methods are implemented, then predictive accuracy for epilepsy susceptibility is improved, but cost of diagnosis increases
Solution Approach 1:
The patent focuses on detecting a specific panel of 5 key miRNA biomarkers rather than performing comprehensive genomic sequencing or proteomic analysis, segmenting the diagnostic approach to achieve high predictive accuracy at reduced cost compared to broader molecular screening methods
Solution Approach 2:
The patent employs disposable oligonucleotide probes for miRNA detection that can be synthesized at low cost and used in single-use diagnostic assays, providing accurate biomarker measurement without the need for expensive reusable equipment or complex infrastructure
3Reliability
If targeted treatment with anti-epileptogenic agents is implemented based on biomarker detection, then treatment efficacy is improved, but loss of time for diagnosis and treatment planning increases
Solution Approach 1:
The patent performs miRNA biomarker detection and epilepsy susceptibility assessment before initiating anti-epileptogenic treatment, allowing clinicians to pre-identify patients who will benefit from targeted therapy, thereby improving treatment efficacy while enabling early intervention rather than delaying treatment
Solution Approach 2:
The patent uses miRNA biomarker levels as feedback indicators to guide treatment decisions, where the presence and concentration of specific biomarkers provide real-time information about epilepsy susceptibility, allowing rapid adjustment of treatment plans without extensive trial-and-error periods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of individuals at risk for epilepsy following TBI, enabling targeted treatment and reducing unnecessary medication use, thereby improving predictive accuracy and treatment efficacy.
Implementation Method 1
contacting the sample with oligonucleotide probes, wherein the oligonucleotide probes specifically hybridize to the polynucleotides of SEQ. ID. NOs. 1-15 in the sample
Implementation Method 2
the oligonucleotides are labeled with at least one fluorescent dye; detecting the fluorescent signals from the hybridization complex
Data Source
Figure 1~2
Figure 3
AI summary
Various embodiments include methods of diagnosing susceptibility to epilepsy in an individual or methods of managing treatment of a neurological condition in an individual, comprising: obtaining a sample from the individual; assaying the sample to determine the presence or absence of one or more biomarkers of epilepsy; and diagnosing susceptibility to epilepsy in the individual based on the presence of one or more biomarkers of epilepsy. Various embodiments further include kits for diagnostic use, comprising a diagnostic panel of one or more of the biomarkers: Let-7d-5p, miR-340-3p, miR-484, miR-151, miR-350, miR-770-5p, miR-139-3p, miR-2985, miR-101a-5p, miR-206-3p, miR-760-3p, miR-383-5p, miR-294, and miR-328a-5p.